# MCF2

## Overview
The MCF2 gene encodes a guanine nucleotide exchange factor (GEF) that plays a pivotal role in cellular signaling by interacting with Rho family GTPases, such as Rho, Rac, and Cdc42. These interactions are crucial for various cellular processes, including actin cytoskeleton organization, cell movement, and proliferation. The protein product of MCF2, known as the DBL proto-oncogene, contains a Dbl homology (DH) domain essential for its GEF activity and a Pleckstrin homology (PH) domain that aids in membrane association, facilitating its function in signal transduction (Hart1994Cellular). MCF2 is subject to alternative splicing, resulting in isoforms with distinct functional properties, and its activity may be regulated by post-translational modifications such as phosphorylation (Komai2003Characterization; Komai2002Alternative). The gene's involvement in critical cellular pathways underscores its importance in maintaining normal cellular function and its potential implications in various diseases, including cardiovascular and psychiatric disorders (Knoblich2018DNA; Maiwald2015A).

## Structure
The MCF2 gene encodes a guanine nucleotide exchange factor (GEF) that interacts with Rho family GTPases, such as Rho, Rac, and Cdc42, playing a crucial role in cellular signaling pathways (Komai2003Characterization). The protein structure includes a Dbl homology (DH) domain, which is essential for its GEF activity, facilitating the exchange of GDP for GTP on Rho GTPases (Hart1994Cellular). The Pleckstrin homology (PH) domain is also present, aiding in membrane association, which is critical for its function in signal transduction (Hart1994Cellular).

MCF2 undergoes alternative splicing, resulting in various isoforms with distinct functional properties. For instance, a brain-specific splice variant omits a 48 bp exon, leading to reduced GEF activity compared to the testis-specific product (Komai2003Characterization). This exon is necessary for full GEF activity, highlighting the functional diversity introduced by alternative splicing (Komai2002Alternative).

Post-translational modifications, such as phosphorylation, may regulate the activity of MCF2, although specific details are not provided in the context. The protein's structure and modifications contribute to its role in modulating cellular processes through Rho GTPase signaling pathways.

## Function
The MCF2 gene encodes a guanine nucleotide exchange factor (GEF) that is involved in the activation of Rho family GTPases, including RhoA, Rac1, and Cdc42. These GTPases play a crucial role in various cellular processes such as actin cytoskeleton organization, cellular movement, proliferation, and apoptosis (Komai2002Alternative). MCF2 facilitates the conversion of these GTPases from their inactive GDP-bound form to their active GTP-bound form, inducing conformational changes that allow interaction with downstream molecular targets (Komai2003Characterization). This activation is essential for intracellular signal transduction pathways that influence cell morphology and motility (Whitehead1997Dbl).

In healthy human cells, MCF2 is active in the cytoplasm and is involved in processes such as neurite outgrowth, which is critical for neuronal development (Knoblich2018DNA). The protein's activity is crucial for cellular responses, including the maturation and organization of skeletal muscle and neurons, as well as the morphogenesis and proliferation of B and T cells (Komai2003Characterization). MCF2's role in these processes underscores its importance in maintaining normal cellular function and organismal development.

## Clinical Significance
Mutations and alterations in the MCF2 gene have been implicated in various diseases and conditions. A rare variant in the MCF2L gene, specifically c.2066A>G (p.Asp689Gly), has been associated with premature atherosclerosis. This variant was identified in a family with a history of premature cardiovascular disease, where it co-segregated with the disease status. Functional assays demonstrated that this variant impairs the activation of Rac1 and RhoA pathways, which are crucial for cellular processes such as stress fiber formation and cell rounding. The presence of MCF2L in atherosclerotic segments of human coronary arteries, but not in non-diseased arteries, suggests its potential role in the pathogenesis of atherosclerosis (Maiwald2015A).

In the context of psychiatric disorders, alterations in the DNA methylation of the MCF2 gene have been studied as potential biomarkers for therapy response in borderline personality disorder (BPD). Hypermethylation of MCF2 was associated with better responses to Dialectical Behavior Therapy, indicating that epigenetic changes in this gene might influence treatment outcomes (Knoblich2018DNA). These findings highlight the clinical significance of MCF2 in both cardiovascular and psychiatric conditions.

## Interactions
MCF2, also known as the DBL proto-oncogene, is a guanine nucleotide exchange factor (GEF) that interacts with Rho family GTPases, including RhoA, Rac1, and Cdc42. These interactions facilitate the exchange of GDP for GTP, which is crucial for the activation of these GTPases and subsequent cellular responses such as cytoskeletal organization and cell migration (Komai2003Characterization; Komai2002Alternative).

MCF2 has been shown to activate RhoA and Cdc42 similarly in both mouse and human gene products, while Rac1 activation is specific to the mouse product (Komai2003Characterization). The protein also interacts with small G proteins, converting them from the GDP-bound to the GTP-bound form, which induces conformational changes allowing interaction with downstream molecular targets (Komai2003Characterization).

There is potential interaction between MCF2 and CAP1 (adenylyl cyclase-associated protein 1), which is involved in actin turnover and cell motility. This suggests a role for MCF2 in coordinating cellular signaling pathways that promote neurite outgrowth and other cellular processes (Okada2011SH3). However, specific physical interactions of MCF2 with other proteins or nucleic acids beyond this potential interaction are not detailed in the available context.


## References


[1. (Knoblich2018DNA) Nora Knoblich, Friederike Gundel, Christof Brückmann, Julia Becker-Sadzio, Christian Frischholz, and Vanessa Nieratschker. Dna methylation of apba3 and mcf2 in borderline personality disorder: potential biomarkers for response to psychotherapy. European Neuropsychopharmacology, 28(2):252–263, February 2018. URL: http://dx.doi.org/10.1016/j.euroneuro.2017.12.010, doi:10.1016/j.euroneuro.2017.12.010. This article has 27 citations and is from a peer-reviewed journal.](https://doi.org/10.1016/j.euroneuro.2017.12.010)

[2. (Okada2011SH3) Hirokazu Okada, Akiyoshi Uezu, Frank M. Mason, Erik J. Soderblom, M. Arthur Moseley, and Scott H. Soderling. Sh3 domain–based phototrapping in living cells reveals rho family gap signaling complexes. Science Signaling, November 2011. URL: http://dx.doi.org/10.1126/scisignal.2002189, doi:10.1126/scisignal.2002189. This article has 36 citations and is from a domain leading peer-reviewed journal.](https://doi.org/10.1126/scisignal.2002189)

[3. (Komai2003Characterization) Koichiro Komai, Naoko Mukae-Sakairi, Michinori Kitagawa, and Shunichi Shiozawa. Characterization of novel splicing variants of the mouse mcf-2 (dbl) proto-oncogene. Biochemical and Biophysical Research Communications, 309(4):906–909, October 2003. URL: http://dx.doi.org/10.1016/j.bbrc.2003.08.088, doi:10.1016/j.bbrc.2003.08.088. This article has 8 citations and is from a peer-reviewed journal.](https://doi.org/10.1016/j.bbrc.2003.08.088)

[4. (Hart1994Cellular) M.J. Hart, A. Eva, D. Zangrilli, S.A. Aaronson, T. Evans, R.A. Cerione, and Y. Zheng. Cellular transformation and guanine nucleotide exchange activity are catalyzed by a common domain on the dbl oncogene product. Journal of Biological Chemistry, 269(1):62–65, January 1994. URL: http://dx.doi.org/10.1016/s0021-9258(17)42313-1, doi:10.1016/s0021-9258(17)42313-1. This article has 245 citations and is from a domain leading peer-reviewed journal.](https://doi.org/10.1016/s0021-9258(17)42313-1)

[5. (Whitehead1997Dbl) Ian P Whitehead, Sharon Campbell, Kent L Rossman, and Channing J Der. Dbl family proteins. Biochimica et Biophysica Acta (BBA) - Reviews on Cancer, 1332(1):F1–F23, February 1997. URL: http://dx.doi.org/10.1016/s0304-419x(96)00040-6, doi:10.1016/s0304-419x(96)00040-6. This article has 44 citations.](https://doi.org/10.1016/s0304-419x(96)00040-6)

[6. (Komai2002Alternative) Koichiro Komai, Rie Okayama, Michinori Kitagawa, Hirofumi Yagi, Kazuo Chihara, and Shunichi Shiozawa. Alternative splicing variants of the human dbl (mcf-2) proto-oncogene. Biochemical and Biophysical Research Communications, 299(3):455–458, December 2002. URL: http://dx.doi.org/10.1016/s0006-291x(02)02645-1, doi:10.1016/s0006-291x(02)02645-1. This article has 16 citations and is from a peer-reviewed journal.](https://doi.org/10.1016/s0006-291x(02)02645-1)

[7. (Maiwald2015A) Stephanie Maiwald, Mahdi M Motazacker, Julian C van Capelleveen, Suthesh Sivapalaratnam, Allard C van der Wal, Chris van der Loos, John J P Kastelein, Willem H Ouwehand, G Kees Hovingh, Mieke D Trip, Jaap D van Buul, and Geesje M Dallinga-Thie. A rare variant in mcf2l identified using exclusion linkage in a pedigree with premature atherosclerosis. European Journal of Human Genetics, 24(1):86–91, April 2015. URL: http://dx.doi.org/10.1038/ejhg.2015.70, doi:10.1038/ejhg.2015.70. This article has 11 citations and is from a domain leading peer-reviewed journal.](https://doi.org/10.1038/ejhg.2015.70)